ArticleDrug design, development and therapy2025
Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial.Nature communications · 2026Trial
- Efficacy and Safety of Cadonilimab in Digestive System Neoplasms: A Systematic Review and Single-Arm Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy is now a cornerstone of first-line treatment for advanced gastric or gastroesophageal junction cancer (G/GEJC). However, optimal second-line options after progression on first-line immunotherapy are undefined. Given the established efficacy of cadonilimab in the first-line setting, this real-world study evaluated its combination with chemotherapy as a second-line treatment. Methods: We conducted a single-center retrospective study of patients with advanced G/GEJC progressing after first-line immunotherapy. Patients received either cadonilimab plus chemotherapy (Cohort A, n=50) or chemotherapy alone (Cohort B, n=62) as second-line therapy between October 2022 and April 2025. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Results: Cohort A showed significantly improved outcomes. Median PFS was 4.9 months (95% CI: 3.9-6.0) in Cohort A vs 3.8 months (95% CI: 2.8-4.8) in Cohort B (p=0.024). Median OS was 10.3 months (95% CI: 8.8-11.8) vs 7.4 months (95% CI: 6.9-7.9), respectively (p=0.046). ORR was 34.0% vs 17.7% (p=0.048), and DCR was 74.0% vs 54.8% (p=0.036). Safety was comparable between cohorts, with no treatment-related deaths. Conclusion: Cadonilimab plus chemotherapy significantly improved efficacy outcomes versus chemotherapy alone in patients with advanced G/GEJC after first-line immunotherapy progression, with a manageable safety profile. This suggests cadonilimab based therapy is a promising second-line strategy. Further prospective randomized studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.